Literature DB >> 26482034

Modern affinity reagents: Recombinant antibodies and aptamers.

Katherine Groff1, Jeffrey Brown2, Amy J Clippinger3.   

Abstract

Affinity reagents are essential tools in both basic and applied research; however, there is a growing concern about the reproducibility of animal-derived monoclonal antibodies. The need for higher quality affinity reagents has prompted the development of methods that provide scientific, economic, and time-saving advantages and do not require the use of animals. This review describes two types of affinity reagents, recombinant antibodies and aptamers, which are non-animal technologies that can replace the use of animal-derived monoclonal antibodies. Recombinant antibodies are protein-based reagents, while aptamers are nucleic-acid-based. In light of the scientific advantages of these technologies, this review also discusses ways to gain momentum in the use of modern affinity reagents, including an update to the 1999 National Academy of Sciences monoclonal antibody production report and federal incentives for recombinant antibody and aptamer efforts. In the long-term, these efforts have the potential to improve the overall quality and decrease the cost of scientific research.
Copyright © 2015 Elsevier Inc. All rights reserved.

Keywords:  Affinity reagents; Antibodies; Aptamers; Ascites antibodies; Recombinant antibodies

Mesh:

Substances:

Year:  2015        PMID: 26482034     DOI: 10.1016/j.biotechadv.2015.10.004

Source DB:  PubMed          Journal:  Biotechnol Adv        ISSN: 0734-9750            Impact factor:   14.227


  26 in total

Review 1.  Recent Advances in Aptamers Targeting Immune System.

Authors:  Piao-Ping Hu
Journal:  Inflammation       Date:  2017-02       Impact factor: 4.092

2.  An engineered ultra-high affinity Fab-Protein G pair enables a modular antibody platform with multifunctional capability.

Authors:  Tomasz Slezak; Lucas J Bailey; Mateusz Jaskolowski; Dominik A Nahotko; Ekaterina V Filippova; Elena K Davydova; Anthony A Kossiakoff
Journal:  Protein Sci       Date:  2019-11-01       Impact factor: 6.725

3.  Replacement of in vivo leptospirosis vaccine potency testing in the United States.

Authors:  Bridget Rogers; Jeffrey Brown; David G Allen; Warren Casey; Amy J Clippinger
Journal:  Biologicals       Date:  2022-06-24       Impact factor: 1.760

4.  Investigation of Conditions for Capture of Live Legionella pneumophila with Polyclonal and Recombinant Antibodies.

Authors:  Lucas Paladines; Walid M Hassen; Juliana Chawich; Stefan Dübel; Simon Lévesque; Jan J Dubowski; Eric H Frost
Journal:  Biosensors (Basel)       Date:  2022-05-31

Review 5.  Point-of-Care Diagnostics: Recent Developments in a Connected Age.

Authors:  Samiksha Nayak; Nicole R Blumenfeld; Tassaneewan Laksanasopin; Samuel K Sia
Journal:  Anal Chem       Date:  2016-12-13       Impact factor: 6.986

6.  CRISPR-Mediated Isogenic Cell-SELEX Approach for Generating Highly Specific Aptamers Against Native Membrane Proteins.

Authors:  Jonah C Rosch; Emma H Neal; Daniel A Balikov; Mohsin Rahim; Ethan S Lippmann
Journal:  Cell Mol Bioeng       Date:  2020-09-11       Impact factor: 2.321

7.  Paper-based MoS2 nanosheet-mediated FRET aptasensor for rapid malaria diagnosis.

Authors:  Alisha Geldert; Chwee Teck Lim
Journal:  Sci Rep       Date:  2017-12-13       Impact factor: 4.379

8.  Antibody fragments as nanoparticle targeting ligands: a step in the right direction.

Authors:  Daniel A Richards; Antoine Maruani; Vijay Chudasama
Journal:  Chem Sci       Date:  2016-09-16       Impact factor: 9.825

9.  Aptamer Combined with Fluorescent Silica Nanoparticles for Detection of Hepatoma Cells.

Authors:  Zixi Hu; Juntao Tan; Zongqiang Lai; Rong Zheng; Jianhong Zhong; Yiwei Wang; Xiaoxue Li; Nuo Yang; Jieping Li; Wei Yang; Yong Huang; Yongxiang Zhao; Xiaoling Lu
Journal:  Nanoscale Res Lett       Date:  2017-02-07       Impact factor: 4.703

10.  Selection and targeting of EpCAM protein by ssDNA aptamer.

Authors:  Walhan Alshaer; Nidaa Ababneh; Mamon Hatmal; Heba Izmirli; Moujab Choukeife; Alaa Shraim; Nour Sharar; Aya Abu-Shiekah; Fadwa Odeh; Abeer Al Bawab; Abdalla Awidi; Said Ismail
Journal:  PLoS One       Date:  2017-12-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.